{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:58:16Z","timestamp":1761170296204,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.hjc.2017.11.004","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T14:30:19Z","timestamp":1510151419000},"page":"293-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"Loukianos S.","family":"Rallidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas S.","family":"Triantafyllis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Iliodromitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hjc.2017.11.004_bib1","first-page":"86","article-title":"PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions","volume":"57","author":"Rallidis","year":"2016","journal-title":"Hell J Cardiol"},{"key":"10.1016\/j.hjc.2017.11.004_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hjc.2017.11.004_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12944-016-0227-2","article-title":"Eligibility for PCSK9 treatment in 734 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol \u2265 70 mg\/dl despite maximal tolerated cholesterol lowering therapy","volume":"15","author":"Glueck","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.hjc.2017.11.004_bib4","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2012.06.057","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA2) bound on high density lipoprotein is associated with lower risk of cardiac death in stable coronary artery disease patients: a three year follow-up","volume":"60","author":"Rallidis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2017.11.004_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjcard.2017.06.002","article-title":"Characteristics and long-term prognosis of patients with premature ST-elevation myocardial infarction and \u201cnormal or near normal\u201d coronary arteries","volume":"120","author":"Rallidis","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hjc.2017.11.004_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hjc.2017.11.004_bib7","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2017.11.004_bib8","first-page":"2245","article-title":"ESC\/EAS Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"issue":"6 Suppl","key":"10.1016\/j.hjc.2017.11.004_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hjc.2017.11.004_bib10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: Recommendations from an expert panel of the National Lipid Association","volume":"11","author":"Orringer","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hjc.2017.11.004_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hjc.2017.11.004_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF03401398","article-title":"Expert consensus on the rational clinical use of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors","volume":"15","author":"Achimastos","year":"2016","journal-title":"Hormones (Athens)"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966617304517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966617304517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:11:52Z","timestamp":1761099112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966617304517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1109966617304517"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2017.11.004","relation":{},"ISSN":["1109-9666"],"issn-type":[{"type":"print","value":"1109-9666"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2017.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}